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CASE
A previously healthy 35-year-old male presented to our hospital in mid-March 2020
with an acute subarachnoid hemorrhage (SAH). The patient had been in the shower
when he experienced a sudden, pounding frontal headache associated with nausea
and vomiting, blurred vision, and weakness. Initial imaging conﬁrmed the presence of
an SAH; follow-up computerized tomography angiography did not identify an aneurysm or other cause for the SAH. The patient’s mental status and oxygenation rapidly
deteriorated. He required intubation to protect his airway and was transferred to the
intensive care unit (ICU) on hospital day zero (HD0). Given the increasing incidence of
coronavirus disease 2019 (COVID-19) at the time and a documented COVID-19 exposure at the patient’s place of work 2 days prior to admission, the clinical team was
concerned that infection with severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) was a potential cause of his respiratory failure. It was not believed that the SAH
was secondary to COVID-19, though infection prevention measures were initiated upon
admission and a nasopharyngeal (NP) swab was submitted from the ICU for molecular
testing. The analysis was performed in our hospital microbiology lab utilizing the Quidel
Lyra SARS-CoV-2 molecular assay and reported a negative result.
He was extubated on HD1 and initially did well from the pulmonary standpoint
while his SAH was under investigation. However, he developed diarrhea and mild
elevations in his liver enzymes on HD7; chest imaging identiﬁed new bilateral airspace
opacities, although the patient did not appear symptomatic from these. A second
COVID-19 test was performed and was negative. On HD9, the patient became tachypneic and complained of worsening dyspnea. Chest X-ray conﬁrmed bilateral pulmonary inﬁltrates concerning for COVID-19; thus, elective intubation was performed along
with repeat molecular testing that was once again negative for SARS-CoV-2. He had a
respiratory pathogen panel (RPP) (BioFire FilmArray Respiratory Panel 2.0) performed
that was positive for rhinovirus/enterovirus and coronavirus 229E. Inﬂammatory markers were not assessed during the ﬁrst week of hospitalization, but the patient exhibited
marked elevations from HD8 onwards. C-reactive protein on HD8 and HD10 measured
at 245.5 and 280.5 mg/liter (reference [Ref] ⱕ10 mg/liter), respectively, and d-dimers
ranged from 794 and 3607 ng/ml between HD9 and HD16 (Ref ⱕ499 ng/ml FEU
[ﬁbrinogen equivalent units]).
The patient was monitored by the infectious disease team throughout his hospital
stay and was continued on COVID-19 isolation precautions despite multiple negative
tests. Speciﬁcally, he had a total of four negative NP swab results (all performed by the
Quidel Lyra assay), submitted on HD1, HD7, HD9, and HD14. He underwent a bronchoalveolar lavage (BAL) on HD15, and a portion of this specimen was sent to a
reference laboratory for SARS-CoV-2 testing. A RPP was repeated on the BAL ﬂuid
August 2020 Volume 58 Issue 8 e01195-20

Journal of Clinical Microbiology

Citation Parikh BA, Bailey TC, Lyons PG,
Anderson NW. 2020. The Brief Case: “Not
positive” or “not sure”—COVID-19-negative
results in a symptomatic patient. J Clin
Microbiol 58:e01195-20. https://doi.org/10
.1128/JCM.01195-20.
Editor Alexander J. McAdam, Boston
Children's Hospital
Copyright © 2020 American Society for
Microbiology. All Rights Reserved.
Address correspondence to Neil W. Anderson,
NAnderson@path.wustl.edu.
For answers to the self-assessment questions and
take-home points, see https://doi.org/10.1128/
JCM.01196-20 in this issue.
Published 23 July 2020

jcm.asm.org 1

Downloaded from http://jcm.asm.org/ on August 19, 2020 at Washington University in St. Louis

The Brief Case: “Not Positive” or “Not Sure”—COVID-19Negative Results in a Symptomatic Patient

The Brief Case

Journal of Clinical Microbiology

specimen at the same time with negative results. He was extubated on HD17 after his
respiratory status improved and discharged on HD20, the same day that his BAL ﬂuid
specimen returned positive for SARS-CoV-2. A speciﬁc cause for the SAH was never
determined, though it was thought to be unrelated to the patient’s SARS-CoV-2
infection.
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DISCUSSION
SARS-CoV-2 is a novel coronavirus, responsible for the COVID-19 pandemic. Infection with SARS-CoV-2 can result in a spectrum of symptoms ranging from mild
shortness of breath and fever to respiratory failure and death. The virus is readily spread
through respiratory droplets. Prompt and accurate diagnosis of SARS-CoV-2 infection is
essential for patient management and implementation of appropriate infection prevention.
The diagnosis of SARS-CoV-2 has relied almost exclusively on molecular testing of
upper and lower respiratory specimens. Of these specimen types, NP swabs have
emerged as the most commonly utilized. One reason for this is that NP swabs strike a
balance between perceived diagnostic performance, ease of collection, and patient
safety. Although certain upper respiratory specimens may be easier to collect (for
example, nasal swabs or oropharyngeal swabs), it has been well established for other
respiratory viruses that sampling of the nasopharynx is needed for adequate sensitivity.
Another reason why NP swabs are so commonly used is the availability of acceptable
testing platforms. As of 7 April 2020 (when the BAL ﬂuid sample for this patient was
sent to a reference laboratory for testing), 28 of the 29 commercially available assays
approved by the FDA for emergency use were for testing on nasopharyngeal swabs
(Table 1). In contrast, only 22 assays were approved for oropharyngeal swabs, 15 for
nasal specimens (aspirates/swabs), 7 for bronchoalveolar lavage specimens, 3 for
sputum specimens, and 3 for tracheal aspirate specimens.
The widespread use of NP swabs for molecular diagnosis may lead to the perception
by many that they are the “gold standard” for diagnostic testing. Paired NP swabs have
been used to evaluate the efﬁcacy of other specimen types, and the need to establish
equivalency to NP swab testing has even been made a requirement by the FDA for
validation of select specimen types. However, this case highlights the peril of relying on
NP swabs as the diagnostic gold standard for SARS-CoV-2.
“False-negative” results are often the result of preanalytical, analytical, and postanalytical factors (Fig. 1). Perhaps one of the most commonly suspected causes of erroneous results is the diagnostic performance of the assay. Given the rapidly developing
availability of different SARS-CoV-2 assays, there is an abundance of testing options
with a relative paucity of performance data. Early comparisons of assays have demonstrated overall similar performances, though recent publications have highlighted
newly recognized differences, such as a low clinical sensitivity of the Abbott ID Now
assay in comparison to others (1). As more comparative data become available, it is
likely that additional differences in assay performance will surface, emphasizing the
need for proper laboratory evaluation. Though the assay utilized in this case (the Quidel
Lyra SARS-CoV-2 assay) has not yet been formally evaluated in the published literature,
our in-house validation supports similar clinical performance to other commercially
available assays (including the Roche 6800 and Cepheid SARS-CoV-2 assays).
Another important consideration is proper specimen collection. Nasopharyngeal
swabs require insertion of the tip of the swab equal to the distance from the nostril to
the outer opening of the ears. Although this may result in patient discomfort, sampling
less aggressively can lead to inadequate sampling of the nasopharynx and falsenegative results. Although some assays (for example, the CDC SARS-CoV-2 assay)
contain PCR targets to ensure adequate sampling, these controls cannot determine
whether the sampling was in the proper anatomic location. Some hospitals (including
our own) have adopted the strategy of having dedicated teams of providers to obtain
NP specimens in order to standardize and optimize collection.
The timing of specimen collection is another variable inﬂuencing positivity. Multiple
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Abbott Molecular
Quidel Corporation
Hologic, Inc.
Roche Molecular Systems, Inc. (RMS)

Centers for Disease Control and
Prevention (CDC)

3/18/2020
3/17/2020
3/16/2020
3/12/2020

2/4/2020

Limit of detection
7.5 ⫻ 104 GCE/ml
500 copies/ml
125 GE/ml
330 copies/ml
250 copies/ml
1 ⫻ 105 copies/ml
500 copies/ml (NP); 242
copies/ml (NS); 1,208
copies/ml (BALF)
100 copies/ml
80 genomic RNA copies/l
1 ⫻ 10⫺2 TCID50 ml
0.009 TCID50/ml (ORF1ab);
0.003 TCID50/ml (E gene)
1 ⫻ 100.5
✓
✓
✓
✓
✓

✓

✓
✓
✓

✓
✓
✓

✓

✓

✓

✓

NA

OP

✓
✓
✓
✓

NP
✓
✓
✓
✓
✓
✓
✓

Added 4/13

Added 4/24

Added 4/13

BALF

Added 4/13

SP

Added 4/13

TA

table includes a summary of assays from major manufacturers and does not include all assays with emergency use authorization (EUA). As of 7 April 2020, 29 commercially available assays were FDA approved for
EUA. Abbreviations: NP, nasopharyngeal; OP, oropharyngeal; NA, nasal (nasal aspirate/swab); BALF, bronchoalveolar lavage ﬂuid; SP, sputum; TA, tracheal aspirate; GCE, genomic copy equivalents; GE, genome equivalents;
TCID50, 50% tissue culture infective doses; RT-PCR, reverse transcription-PCR.

CDC 2019-nCoV Real-Time RT-PCR
Diagnostic Panel (CDC)

Abbott RealTime SARS-CoV-2 assay
Lyra SARS-CoV-2 assay
Panther Fusion SARS-CoV-2 assay
cobas SARS-CoV-2

Assay name
Aries SARS-CoV-2 assay
QIAstat-Dx Respiratory SARS-CoV-2
ID Now COVID-19
BioFire COVID-19 test
Xpert Xpress SARS-CoV-2 test
ePlex SARS-CoV-2 test
Simplexa COVID-19 Direct assay

Specimen type
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Company
Luminex Corporation
Qiagen GmbH
Abbott Diagnostics Scarborough, Inc.
BioFire Defense, LLC
Cepheid
GenMark Diagnostics, Inc.
DiaSorin Molecular LLC

Date of EUA
(mo/day/yr)
4/3/2020
3/30/2020
3/27/2020
3/23/2020
3/20/2020
3/19/2020
3/19/2020

TABLE 1 Summary of SARS-CoV-2 testing offered under FDA emergency use authorizationa
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FIG 1 False-negative SARS-CoV-2 test results can be caused by preanalytical, analytical, and postanalytical factors. Mitigation strategies can be used to either prevent false-negative results from occurring
or prevent adverse patient events secondary to false-negative results.

studies demonstrate that the amount of virus present in the upper respiratory tract
varies over the course of infection (2, 3), suggesting that viral loads are highest
immediately following symptom onset and that virus can often be detected in upper
respiratory specimens for greater than 2 weeks postsymptom onset (3). However, cases
like ours suggest that even with multiple collections performed throughout the disease
course, false-negative results can still occur. These types of occurrences may be difﬁcult
to account for in prospective studies, since the majority of these patients will be
diagnosed as SARS-CoV-2 negative, and may therefore not receive follow-up testing.
Differences in specimen type performance may also contribute to discordant results.
Recent data suggest that NP and sputum viral loads are closely related (4). However,
several studies have demonstrated more-reliable results from nasal swabs compared to
throat swabs early in the disease course (2, 3). Case reports of SARS-CoV-2 detection in
sputum, tracheal aspirate, and BAL ﬂuid specimens suggest that these specimens may
be positive when NP swabs are negative, though large-scale studies have yet to be
published (5). Even if such studies were to be performed, they may be biased, as only
the most critically ill patients would be tested using lower respiratory specimens.
Overall availability of lower respiratory testing is also a challenge to obtaining these
data. At the time when our patient was tested, only 8 of 29 FDA emergency use
authorized (EUA) assays allowed testing of BAL ﬂuid specimens. Our available in-house
tests were not authorized for BAL ﬂuid samples, though sending out testing from
August 2020 Volume 58 Issue 8 e01195-20
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alternative sample types was not an initial consideration for our clinicians, who were
concerned about increased turnaround time and had the perception that NP swabs
could give equivalent results to a more invasive test.
It has become clear that negative NP swabs alone do not rule out SARS-CoV-2
infection, and as of now, there is no single “ideal” specimen for the diagnosis of
COVID-19 (5). Consequently, regulatory agencies may have to reevaluate standards
used to assess new assays and specimen types, and clinicians may need to reconsider
how they establish or exclude a diagnosis of COVID-19. Professional agencies have
already recognized the need for additional diagnostic strategies involving more than
just a single test. Updated IDSA (Infectious Diseases Society of America) guidelines for
COVID-19 diagnosis describe an algorithmic approach based on patient symptomatology, suspicion for infection, hospitalization status, and availability of lower respiratory
specimens (6). As tools like serologic testing become more readily available, the “case
deﬁnition” of SARS-CoV-2 infection is likely to mature, which should allow for better
evaluation and reﬁnement of diagnostic strategies.
This case illustrates how reliance on a single test from a single specimen type to rule
out SARS-CoV-2 infection can be problematic. Of note, the health care providers caring
for this patient had a strong suspicion for COVID-19 throughout the hospitalization, and
as such maintained appropriate infection prevention protocols. This case emphasizes
the importance of considering clinical presentation and the necessity for its inclusion in
any diagnostic algorithm for COVID-19. Even in the setting of a public health crisis with
a novel pathogen, the old adage still rings true: treat the patient, not the result.
SELF-ASSESSMENT QUESTIONS
1. Which of the following best describes potential reasons for false-negative molecular testing for SARS-CoV-2?
a. Analytical errors involving improper transport and storage of specimens
b. Preanalytical errors stemming from the limited sensitivity of the molecular test
c. Analytical errors due to incorrect sampling by the clinician obtaining the specimen for testing
d. Preanalytical errors related to interfering substances inhibiting molecular
testing
2. A patient in acute respiratory distress is admitted to the ICU, with strong clinical
suspicion of SARS-CoV-2 infection. Initial molecular testing on admission is
negative for SARS-CoV-2 RNA. What should additional clinical management of
this patient include?
a. Assume the patient is negative to avoid overuse of personal protective equipment
b. Test lower respiratory tract samples if available to help confirm the diagnosis of
COVID-19
c. Perform chest X-ray to confirm negative result and definitively rule out
COVID-19
d. Perform antibody testing to confirm negative result and definitively rule out
COVID-19
3. Which of the following described processes would result in the best sampling of
the nasopharynx for COVID-19 testing?
a. A single flocked swab inserted into the nares to a depth equal to the distance
from the nares to the opening of the ears
b. A single flocked swab inserted into the oral cavity to the back of the throat past
the palatine tonsils
c. A single flocked swab inserted 3 cm deep into the right nares and then reinserted
3 cm deep into the left nares
d. A single flocked swab inserted into the nares to a depth equal to the distance
from the nares to the eyes
August 2020 Volume 58 Issue 8 e01195-20

jcm.asm.org 5

The Brief Case

Journal of Clinical Microbiology

ACKNOWLEDGMENTS
We thank the Barnes Jewish hospital clinical and laboratory health care teams for
their exceptional patient care.

August 2020 Volume 58 Issue 8 e01195-20

4. Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. 2020. Viral load of SARSCoV-2 in clinical samples. Lancet Infect Dis 20:411– 412. https://doi.org/
10.1016/S1473-3099(20)30113-4.
5. Winichakoon P, Chaiwarith R, Liwsrisakun C, Salee P, Goonna A, Limsukon
A, Kaewpoowat Q. 2020. Negative nasopharyngeal and oropharyngeal
swabs do not rule out COVID-19. J Clin Microbiol 58:e00297-20. https://
doi.org/10.1128/JCM.00297-20.
6. Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC,
Edwards KM, Gandhi R, Muller WJ, O’Horo JC, Shoham S, Murad MH,
Mustafa RA, Sultan S, Falck-Ytter Y. 27 April 2020. Infectious Diseases
Society of America guidelines on the treatment and management of
patients with COVID-19. Clin Infect Dis https://doi.org/10.1093/cid/
ciaa478.

jcm.asm.org 6

Downloaded from http://jcm.asm.org/ on August 19, 2020 at Washington University in St. Louis

REFERENCES
1. Harrington A, Cox B, Snowdon J, Bakst J, Ley E, Grajales P, Maggiore J,
Kahn S. 23 April 2020. Comparison of Abbott ID Now and Abbott
m2000 methods for the detection of SARS-CoV-2 from nasopharyngeal
and nasal swabs from symptomatic patients. J Clin Microbiol https://
doi.org/10.1128/JCM.00798-20.
2. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, Yu J, Kang M, Song
Y, Xia J, Guo Q, Song T, He J, Yen HL, Peiris M, Wu J. 2020. SARS-CoV-2 viral
load in upper respiratory specimens of infected patients. N Engl J Med
382:1177–1179. https://doi.org/10.1056/NEJMc2001737.
3. Xiao AT, Tong YX, Gao C, Zhu L, Zhang YJ, Zhang S. 2020. Dynamic proﬁle
of RT-PCR ﬁndings from 301 COVID-19 patients in Wuhan, China: a
descriptive study. J Clin Virol 127:104346. https://doi.org/10.1016/j.jcv
.2020.104346.

